Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Reviva Pharmaceuticals Hldg Inc (RVPH)

Reviva Pharmaceuticals Hldg Inc (RVPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,984
  • Shares Outstanding, K 115,059
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,920 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.43
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.46
  • Most Recent Earnings $-0.06 on 11/13/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 214.35% (-121.97%)
  • Historical Volatility 84.42%
  • IV Percentile 45%
  • IV Rank 16.15%
  • IV High 957.60% on 07/01/25
  • IV Low 71.19% on 08/21/25
  • Expected Move (DTE 5) 0.2465 (94.59%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 204
  • Volume Avg (30-Day) 667
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 144,498
  • Open Int (30-Day) 159,446
  • Expected Range 0.0141 to 0.5071

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 3
  • High Estimate -0.04
  • Low Estimate -0.06
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2540 +2.60%
on 02/05/26
0.3660 -28.80%
on 01/16/26
-0.0944 (-26.59%)
since 01/13/26
3-Month
0.2500 +4.24%
on 12/24/25
0.7700 -66.16%
on 12/11/25
-0.2805 (-51.84%)
since 11/13/25
52-Week
0.2500 +4.24%
on 12/24/25
1.8800 -86.14%
on 02/18/25
-1.5394 (-85.52%)
since 02/13/25

Most Recent Stories

More News
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine...

RVPH : 0.2606 (+1.64%)
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies...

RVPH : 0.2606 (+1.64%)
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the...

RVPH : 0.2606 (+1.64%)
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 –  – Potential NDA submission for schizophrenia indication targeted for Q2 2026...

RVPH : 0.2606 (+1.64%)
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025

CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies...

RVPH : 0.2606 (+1.64%)
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis

- Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine...

RVPH : 0.2606 (+1.64%)
Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference

CUPERTINO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies...

RVPH : 0.2606 (+1.64%)
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies...

RVPH : 0.2606 (+1.64%)
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies...

RVPH : 0.2606 (+1.64%)
Analysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF) and Reviva Pharmaceuticals Holdings (RVPH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Santhera Pharmaceuticals Holding (SPHDF – Research Report) and Reviva Pharmaceuticals Holdings (RVPH –...

RVPH : 0.2606 (+1.64%)
SPHDF : 16.2800 (+4.16%)

Business Summary

Reviva Pharmaceuticals Inc. is a clinical stage pharmaceutical company. It engages in developing therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases. The company's lead product candidate includes RP5063, for the treatment...

See More

Key Turning Points

3rd Resistance Point 0.2879
2nd Resistance Point 0.2802
1st Resistance Point 0.2704
Last Price 0.2606
1st Support Level 0.2529
2nd Support Level 0.2452
3rd Support Level 0.2354

See More

52-Week High 1.8800
Fibonacci 61.8% 1.2573
Fibonacci 50% 1.0650
Fibonacci 38.2% 0.8727
Last Price 0.2606
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar